Chinese Journal of Cancer Research最新文献

{"title":"Cancer statistics in China: Epidemiology, risk factors, and prevention.","authors":"Wei Cao, Kang Qin, Bingyang Liu, Wanqing Chen","doi":"10.21147/j.issn.1000-9604.2025.06.04","DOIUrl":"10.21147/j.issn.1000-9604.2025.06.04","url":null,"abstract":"<p><p>Cancer is a leading cause of death in China, and its epidemiological profile has shifted markedly in recent years. This review summarizes contemporary trends in cancer incidence and mortality, delineates the major modifiable risk factors, and highlights recent national efforts to ease the burden of cancer. In 2022, China recorded 4.8 million new cancer cases (crude rate: 341.7 per 100,000) and 2.5 million cancer deaths (182.3 per 100,000). Lung, colorectal, thyroid, liver, stomach, and female breast cancers accounted for 65% of all diagnoses, while lung, liver, stomach, colorectal, and esophageal cancers constituted 67.5% of cancer deaths. Notable shifts in sex-specific rankings underscored the rising mortality burden of prostate, female breast, and cervical cancers. China has made measurable progress in cancer control. Between 2000 and 2018, the age-standardized mortality rate for all cancers declined by approximately 1.3% annually, and the age-standardized 5-year relative survival improved from 30.9% in 2003-2005 to 43.7% in 2019-2021. According to Global Burden of Disease (GBD) 2023, nearly half of cancer deaths and disability-adjusted life years (DALYs) were attributable to modifiable risk factors such as tobacco, air pollution, high alcohol use, dietary risks, and unsafe sex. In response, the government has implemented a suite of prevention-oriented policies, including expansion of human papillomavirus (HPV) vaccination, strengthened tobacco control, sustained air pollution reduction, enhanced health education, and broadened cancer screening coverage. Collectively, these initiatives demonstrate a sustained national commitment to reducing the cancer burden.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 6","pages":"912-928"},"PeriodicalIF":6.3,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12780754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer.","authors":"Facai Zhang, Yunkai Yang, Rong Zhang, Huan Hu, Chuanzan Zhou, Jie Wang, Ruicheng Wu, Enhui Li, William C Cho, Dahong Zhang, Qi Zhang, Dechao Feng","doi":"10.21147/j.issn.1000-9604.2025.06.13","DOIUrl":"10.21147/j.issn.1000-9604.2025.06.13","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Cisplatin-based chemotherapy is a cornerstone for bladder cancer treatment, but the development of resistance remains a major clinical challenge. Curcumol, a bioactive sesquiterpenoid derived from &lt;i&gt;Curcumae Rhizoma&lt;/i&gt;, has shown anti-tumor potential. This study investigated the efficacy of curcumol in overcoming cisplatin resistance and elucidated its underlying molecular mechanisms in bladder cancer progression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Clinical correlation was assessed in patients receiving neoadjuvant chemotherapy with or without &lt;i&gt;Curcumae Rhizoma&lt;/i&gt;. The anti-tumor effects of curcumol were evaluated in both cisplatin-sensitive and cisplatin-resistant bladder cancer cells. Multi-omics approaches, including RNA sequencing, proteomics and metabolomics, were employed. Key mechanisms involving H3K9 lactylation (H3K9la) were explored via Western blotting, immunohistochemistry, and cleavage under targets and tagmentation (CUT&Tag) assays. The role of the identified target ORC6 was validated through genetic knockout and overexpression. Finally, ferroptosis was confirmed by measuring lipid peroxidation [malondialdehyde (MDA)], total iron levels, and ferroptosis-related protein markers &lt;i&gt;in vitro&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Clinical data indicated that patients administered &lt;i&gt;Curcumae Rhizoma&lt;/i&gt; exhibited enhanced responses to neoadjuvant chemotherapy. In addition, curcumol suppressed the proliferation, migration, and invasion of both bladder cancer cells and cisplatin-resistant cells. Mechanistically, proteomic analysis and non-targeted metabolomics revealed that curcumol suppresses glycolysis and lactate production. Subsequently, Western blotting analysis demonstrated a marked reduction in H3K9la levels in both T24 and 5637 cells following curcumol treatment. This decrease in H3K9la was also observed in patient tumor tissues via immunohistochemistry staining. CUT&Tag analysis identified that H3K9la is enriched with the highest number of reads at the ORC6 promoter region. Combined &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; experiments indicated that OCR6 exerted a tumor-promoting effect on bladder cancer. Its knockout induced G0/G1 phase arrest and enhanced apoptosis, while its expression contributed to cancer progression by enhancing invasive and migratory capabilities. Furthermore, ORC6 overexpression correlated with ferroptosis scores and ferroptosis-related genes. &lt;i&gt;In vitro&lt;/i&gt;, OCR6 knockout promoted ferroptosis via DNA damage, characterized by elevated MDA content, decreased expression of core ferroptosis-related proteins (GPX4 and SLC7A11), increased percentage of γH2AX-positive cells and longer DNA tails. Finally, we performed rescue experiments using a ferroptosis inhibitor in ORC6 knockout cells, which indicated that ferroptosis inhibitor could weaken the effect of ORC6 knockout on the invasive, migratory, and proliferative capacities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our findings demonstr","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 6","pages":"1034-1057"},"PeriodicalIF":6.3,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12780774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haploidentical donor <i>vs</i>. human leukocyte antigen-matched donor hematopoietic cell transplantation for elderly patients with hematologic malignancies: Inferior non-relapse mortality but comparable survival.","authors":"Mengqi Xiang, Xiang Zhang, Mimi Xu, Yuqing Tu, Juan Shen, Xiaoli Li, Xiaojin Wu, Suning Chen, Ying Wang, Yue Han, Miao Miao, Aining Sun, Huiying Qiu, Yi Fan, Depei Wu, Jia Chen","doi":"10.21147/j.issn.1000-9604.2025.05.06","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.06","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"737-741"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of short- and long-term outcomes of robotic <i>vs</i>. laparoscopic gastrectomy for clinical serosa-invasive gastric cancer: A multicenter cohort study.","authors":"Hualong Zheng, Zhiwei Zheng, Honghong Zheng, Taiyuan Li, Linghua Wei, Li Zhang, Junjun She, Baoqing Jia, Xingan Qin, Shuangyi Ren, Hongliang Yao, Zhen Xue, Lingkang Zhang, Jiabin Wang, Changming Huang, Ping Li","doi":"10.21147/j.issn.1000-9604.2025.05.13","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.13","url":null,"abstract":"<p><strong>Objective: </strong>Robotic gastrectomy (RG) is increasingly used in the treatment of gastric cancer. However, studies on patients with clinical serosa-invasive (cT4a) gastric cancer remain scarce. This study aimed to compare the short- and long-term outcomes of RG and laparoscopic gastrectomy (LG) in the treatment of stage cT4a gastric cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of patients with stage cT4a gastric cancer diagnosed and treated at eight high-volume tertiary teaching hospitals in China from 2016 to 2019. Propensity score matching (PSM) analysis and inverse probability of treatment weighting (IPTW) analysis was used to adjust for the imbalance in baseline characteristics. The primary research endpoint was the 3-year overall survival (OS) and disease-free survival (DFS). The secondary research endpoint was intraoperative outcomes and postoperative complications.</p><p><strong>Results: </strong>After IPTW and PSM adjustments, baseline characteristics between the RG and LG groups were comparable [standardized mean difference (SMD) <0.10]. Post-PSM analysis revealed that the RG group exhibited longer operative time (P<0.001), lower postoperative complication rates (P<0.001), shorter postoperative hospital stays (P=0.037), and earlier initiation of adjuvant chemotherapy (P=0.041) compared with the LG group. Survival analysis demonstrated comparable 3-year OS (P=0.110) and DFS (P=0.088) in the PSM cohort, whereas the IPTW cohort showed superior OS (P=0.030) and DFS (P=0.046) for RG. No significant differences were observed in overall recurrence rates or recurrence sites between groups.</p><p><strong>Conclusions: </strong>For patients with stage cT4a gastric cancer, compared with the LG group, the RG group had shorter postoperative hospital stay, lower incidence of postoperative complications, earlier postoperative adjuvant chemotherapy, and no worse long-term efficacy.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"837-850"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma.","authors":"Wei Xia, Jiwei Liu, Ruo Chen, Junjie Feng, Lei Wu, Yize Wang, Xiaokun Wang, Chenghu Song, Wenjun Mao","doi":"10.21147/j.issn.1000-9604.2025.05.11","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.11","url":null,"abstract":"<p><strong>Objective: </strong>A highly aggressive and lethal malignancy, characterized by its heterogeneity, lung adenocarcinoma (LUAD) presents significant challenges in prognosis and treatment. Disulfidptosis, a newly identified form of regulated cell death, offers novel insights into cancer progression, yet its role in LUAD remains poorly understood.</p><p><strong>Methods: </strong>We identified disulfidptosis-related genes (DRGs) from prior studies and analyzed their interactions and functional enrichment. Molecular subtypes were identified through consensus clustering based on DRG expression, and a prognostic DRG signature was developed using multivariate Cox regression analysis. A nomogram integrating clinical variables was developed to predict survival. Comprehensive analyses, including single-cell RNA sequencing, immune infiltration, and drug sensitivity, were validated using clinical specimens, LUAD cell lines, Western blotting (WB) and immunohistochemistry (IHC).</p><p><strong>Results: </strong>A total of 16 DRGs were identified, classifying LUAD patients into three distinct subtypes with differential survival and immune profiles. A 4-gene signature (<i>GYS1</i>, <i>NDUFA11</i>, <i>NDUFB10</i>, <i>SLC7A11</i>) was used to build a risk score model, demonstrating robust prognostic accuracy. A nomogram combining this signature with clinical features reliably predicted 1-, 3-, and 5-year survival. The signature correlated with immune cell infiltration, with single-cell analysis revealing DRG enrichment in myeloid cells. Notably, <i>SLC7A11</i> and <i>GYS1</i> were positively associated with chemotherapeutic drug sensitivity. Validation through reverse transcription quantitative polymerase chain reaction (RT-qPCR), WB and IHC confirmed upregulated DRG expression in LUAD tissues and cell lines.</p><p><strong>Conclusions: </strong>This research highlights the essential role of DRGs in modulating the tumor microenvironment, influencing therapeutic response, and determining the prognosis of LUAD. The risk model and nomogram, derived from DRG expression, offer robust tools for survival prediction and personalized treatment stratification, facilitating the development of disulfidptosis-targeted therapeutic strategies.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"796-820"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12614471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic transplantation in adverse-risk acute myeloid leukemia: Challenges, strategies, and future directions.","authors":"Jingtao Huang, Xinyi Wu, Gaoxiang Wang, Yang Cao, Xiaoxia Hu, On Behalf Of Trophy Working Group","doi":"10.21147/j.issn.1000-9604.2025.05.05","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.05","url":null,"abstract":"<p><p>Adverse-risk acute myeloid leukemia (AML) is a therapeutic challenge despite advances in risk stratification. Unmet needs persist in high-risk molecular subgroups, such as AML with myelodysplasia-related changes, <i>TP53</i> mutations, or rearrangements involving <i>NUP98</i>, <i>NUP214</i>, or <i>FUS::ERG</i>. These subtypes are associated with poor responses to conventional induction therapies and high relapse rates. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the cornerstone of consolidation for eligible patients; however, due to high relapse rates, regimen-related toxicity, and variable responses across genetic subtypes, optimal transplant timing, conditioning regimens (e.g., busulfan- or melphalan-based protocols), and bridging strategies require further refinement. Meanwhile, post-transplant maintenance therapies, such as hypomethylating agents or targeted drugs, are one emerging area under investigation for relapse prevention. In this perspective, we review the latest advances in allo-HSCT strategies for adverse-risk AML and highlight the importance of molecularly-guided approaches to improve outcomes in these aggressive subtypes.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"718-736"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.","authors":"Yulun Chen, Siqi Li, Xiaosu Zhao, Yingjun Chang","doi":"10.21147/j.issn.1000-9604.2025.05.02","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.02","url":null,"abstract":"<p><p>Measurable residual disease (MRD) has become a critical biomarker in the management of acute lymphoblastic leukemia (ALL), particularly for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The incorporation of MRD-directed strategies into clinical practice can enable personalized therapy and improve outcomes in ALL patients. Growing evidence has demonstrated that MRD status not only reflects the treatment response and relapse risk but also informs clinical decisions across the transplant continuum, including transplant indications, donor selection, conditioning regimens, and post-transplant interventions. With the advent of highly sensitive technologies such as real-time polymerase chain reaction and next-generation sequencing, MRD assessment has reached unprecedented accuracy, enabling precision medicine for ALL. This review systematically addresses six key clinical questions related to the application of MRD in ALL patients undergoing transplantation. We discuss optimal MRD detection methods, timing and sampling strategies, the prognostic implications of MRD positivity or clearance, and MRD-directed approaches before and after allo-HSCT. We further highlight emerging immunotherapeutic options and research gaps that must be addressed to refine MRD-guided strategies. In summary, incorporating MRD evaluation into routine clinical practice has the potential to optimize transplant outcomes and reduce relapse in ALL patients.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"667-685"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma cell-free DNA methylation markers for detection and prognosis of gastric cancer: A case-control study.","authors":"Yanan Wang, Longyang Jin, Weiyang He, Jiaxi Peng, Kailai Yin, Xuanhui Liu, Pengcheng Yu, Yi Wang, Zhehan Bao, Yuhang Xia, Fengming Zhang, Chun Song, Li Yuan, Yuying Wang, Lei Lian, Xiaodong Chen, Xiangdong Cheng","doi":"10.21147/j.issn.1000-9604.2025.05.14","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.14","url":null,"abstract":"<p><strong>Objective: </strong>Plasma cell-free DNA (cfDNA) methylation has shown potential in the detection and prognostic testing of multiple cancers. Here, we comprehensively investigate the performance of cfDNA methylation for gastric cancer (GC) detection and prognosis.</p><p><strong>Methods: </strong>GC-specific differentially methylated regions (DMRs) were identified by sequencing 56 GC tissues and 59 normal adjacent tissues (NATs). We then performed targeted bisulfite sequencing of cfDNA from 294 GC and 446 non-gastric cancer (NGC) plasma samples, identifying 179 DMRs that overlapped with those in tissue samples. The efficacy of plasma cfDNA methylation markers for GC detection and prognosis was evaluated.</p><p><strong>Results: </strong>Based on the 179 DMRs overlapping with those in tissue samples, the random forest (RF) model using 28 DMRs achieved an area under the curve (AUC) of 0.998 in the training cohort, whereas further refinement to the top 6 DMRs resulted in an AUC of 0.985. Consistent results were obtained in the validation cohort (28 DMR AUC: 0.985; 6 DMR AUC: 0.988). Support vector machine (SVM) and logistic regression (LR) models also demonstrated robust performance. Additionally, an 11-DMR signature was developed for prognostic prediction, successfully identifying high-risk GC patients with significantly shorter overall survival.</p><p><strong>Conclusions: </strong>Our study highlights the potential utility of cfDNA methylation markers for both the detection and prognostication of GC.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"851-864"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HBV reactivation and its metabolomic profile after liver transplantation for hepatocellular carcinoma in non-alcoholic steatohepatitis.","authors":"Jinyan Chen, Leyi Chen, Huigang Li, Zhihang Hu, Jianyong Zhuo, Xingzhu Chen, Ruijie Zhao, Chiyu He, Xiang Wu, Zhanyi Lin, Jiancai Sun, Rongsen Wang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu","doi":"10.21147/j.issn.1000-9604.2025.05.15","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.15","url":null,"abstract":"<p><strong>Objective: </strong>The role of non-alcoholic steatohepatitis (NASH) in hepatitis B virus (HBV) reactivation following liver transplantation for hepatocellular carcinoma (HCC) remains unclear, and the metabolic differences between patients with NASH and those with HBV reactivation are also yet to be elucidated. This study is to investigate the impact of NASH on HBV reactivation risk and prognosis following liver transplantation for HCC, and to develop a predictive model and identify therapeutic targets.</p><p><strong>Methods: </strong>This study included 274 patients who underwent liver transplantation for HCC. The HBV reactivation status of patients with NASH was analyzed, and the metabolic characteristics of peripheral blood were examined to compare NASH and non-NASH patients with or without HBV reactivation.</p><p><strong>Results: </strong>The HBV reactivation free survival was better in non-NASH patients (P<0.0001). Furthermore, NASH patients with HBV reactivation had worse recurrence-free survival (RFS) than non-NASH patients with HBV reactivation (P=0.016). In contrast, the RFS of NASH patients without HBV reactivation was comparable to that of non-NASH patients without HBV reactivation (P=0.810). Subsequently, we constructed a model to predict HBV reactivation by incorporating 7 clinical indicators using the Least Absolute Shrinkage and Selection Operator-Cox (LASSO-Cox) approach. The area under the receiver operating characteristic curve (AUROC) values for predictions at 500, 1,000, and 1,500 d were 0.759, 0.809, and 0.814, respectively. Finally, metabolic pathway analysis identified key pathways involved in HBV reactivation, and glutamine was found to be an independent protective factor against HBV reactivation following liver transplantation for HCC.</p><p><strong>Conclusions: </strong>NASH patients are more prone to HBV reactivation following liver transplantation for HCC and exhibit worse recurrence-free survival. Glutamine may serve as a potential therapeutic target or predictive biomarker for HBV reactivation.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"865-878"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of [⁶⁸Ga]Ga-RM2 positron emission tomography imaging on staging and prognosis in estrogen receptor-positive breast cancer: A pilot study.","authors":"Jin Ding, Huan Ma, Xiaoyi Guo, Futao Liu, Qing Xie, Yan Zhang, Zhi Yang, Deling Li, Guohong Song, Hua Zhu","doi":"10.21147/j.issn.1000-9604.2025.05.09","DOIUrl":"10.21147/j.issn.1000-9604.2025.05.09","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the clinical utility of [⁶⁸Ga]Ga-RM2 positron emission tomography/computed tomography (PET/CT), in comparison with ¹⁸F-fluorodeoxyglucose ([¹⁸F]FDG) PET/CT, for staging and prognosis in patients with estrogen receptor-positive (ER+) breast cancer.</p><p><strong>Methods: </strong>This prospective study enrolled nine female patients with breast cancer (mean age 45.5±11.5 years). Eight patients were confirmed to have ER+ disease. All participant underwent both [⁶⁸Ga]Ga-RM2 PET/CT and [¹⁸F]FDG PET/CT scans within a one-week interval. The maximum standardized uptake values (SUV_max) was measured for primary tumors, lymph nodes, and metastatic lesions. The physiological distribution of [⁶⁸Ga]Ga-RM2 was also evaluated.</p><p><strong>Results: </strong>No adverse events were observed. Metastatic were identified in lymph nodes (n=29 lesions), bone (n=19), liver (n=7), brain (n=3), and multiple other sites. [⁶⁸Ga]Ga-RM2 demonstrated a significantly higher median SUV_max than [¹⁸F]FDG across all lesions [7.5 (interquartile range, IQR, 3.4-14.0) <i>vs</i>. 4.0 (IQR, 2.3-6.1); P<0.001]. Similarly, the tumor-to-background ratio (TBR) was significantly superior with [⁶⁸Ga]Ga-RM2 for all type of lesions: primary tumors [12.3 (IQR, 10.4-18.3) <i>vs</i>. 7.0 (IQR, 6.0-10.0); P<0.001], lymph node metastases [17.8 (IQR, 4.4-39.0) <i>vs.</i> 4.7 (IQR, 2.7-10.2); P<0.001], hepatic metastases [5.4 (IQR, 3.7-8.3) <i>vs</i>. 1.0 (IQR, 0.9-1.5); P<0.001], and osseous metastases [13.9 (IQR, 7.3-18.0) <i>vs</i>. 4.3 (IQR, 1.6-5.9); P<0.001]. Physiological uptake of [⁶⁸Ga]Ga-RM2 was the highest in the pancreas (SUV_max, 77.82±22.64), with moderate uptake in the kidneys (2.82±0.62), heart (1.83±0.29), and liver (1.33±0.41).</p><p><strong>Conclusions: </strong>[⁶⁸Ga]Ga-RM2 PET/CT demonstrates superior uptake metrics for the detection of metastatic lesions, particularly in the brain and breast, suggesting its potential as a valuable complementary imaging modality to [¹⁸F]FDG PET/CT. These promising foundings warrant further validation in larger cohorts to confirm their clinical impact and to standardize imaging protocols.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 5","pages":"771-780"},"PeriodicalIF":6.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}